House panel supports 12-year exclusivity for biotech drugs

08/3/2009 | Wall Street Journal, The

The House Energy and Commerce Committee voted 47-11 to approve a measure that would give 12 years of market protection to brand-name biotech medicines. The amendment "takes a balanced approach between innovation, cost savings for consumers and safety," said a spokeswoman for Rep. Jay Inslee, D-Wash., one of the sponsors of the bill.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY